Determining the extent and stage of disease in patients with newly diagnosed non-Hodgkin?s lymphoma using 18F-FDG-PET/CT
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F11%3A00052521" target="_blank" >RIV/00216224:14110/11:00052521 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11110/11:11010 RIV/61989592:15110/11:33115933 RIV/00064165:_____/11:11010
Výsledek na webu
<a href="http://dx.doi.org/10.4149/neo_2011_04_291" target="_blank" >http://dx.doi.org/10.4149/neo_2011_04_291</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.4149/neo_2011_04_291" target="_blank" >10.4149/neo_2011_04_291</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Determining the extent and stage of disease in patients with newly diagnosed non-Hodgkin?s lymphoma using 18F-FDG-PET/CT
Popis výsledku v původním jazyce
Positron emission tomography (PET) using 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (18F-FDG) combined with computed tomography (CT) represents a three-dimensional imaging method suitable for staging in patients with non-Hodgkin?s lymphomas (NHLs). The aimof our prospective multicenter study was to assess the value of initial PET/CT as compared with CT and PET alone for determining the stage and extent of the disease. A total of 122 patients with newly diagnosed NHL were examined using PET/CT. Four patients with resected lymphoma lesion and negative PET/CT were therefore excluded from the study. Of the remaining 118 cases, a total of 117 (99%) were described as 18F-FDG-avid. When compared with PET/CT, CT and PET showed very good sensitivity of lymph node imaging (97% and 100%, respectively); the specificity, however, was significantly lower (66.7% and 94.4%, respectively; p=0.0001). When detecting organ lesions, the sensitivity of CT and PET was lower than that of PET/CT (92.5% and 96.
Název v anglickém jazyce
Determining the extent and stage of disease in patients with newly diagnosed non-Hodgkin?s lymphoma using 18F-FDG-PET/CT
Popis výsledku anglicky
Positron emission tomography (PET) using 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (18F-FDG) combined with computed tomography (CT) represents a three-dimensional imaging method suitable for staging in patients with non-Hodgkin?s lymphomas (NHLs). The aimof our prospective multicenter study was to assess the value of initial PET/CT as compared with CT and PET alone for determining the stage and extent of the disease. A total of 122 patients with newly diagnosed NHL were examined using PET/CT. Four patients with resected lymphoma lesion and negative PET/CT were therefore excluded from the study. Of the remaining 118 cases, a total of 117 (99%) were described as 18F-FDG-avid. When compared with PET/CT, CT and PET showed very good sensitivity of lymph node imaging (97% and 100%, respectively); the specificity, however, was significantly lower (66.7% and 94.4%, respectively; p=0.0001). When detecting organ lesions, the sensitivity of CT and PET was lower than that of PET/CT (92.5% and 96.
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FD - Onkologie a hematologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
<a href="/cs/project/NR9502" target="_blank" >NR9502: Integrovaná FDG-positronová emisní a počítačová tomografie jako základní zobrazovací metoda hodnocení nemocných s ne-hodgkinskými lymfomy</a><br>
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2011
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Neoplasma
ISSN
0028-2685
e-ISSN
—
Svazek periodika
58
Číslo periodika v rámci svazku
4
Stát vydavatele periodika
SK - Slovenská republika
Počet stran výsledku
7
Strana od-do
291-297
Kód UT WoS článku
000290695900003
EID výsledku v databázi Scopus
—